UC Davis Health tests new antibody combination as potential treatment for COVID-19

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, is leading efforts at UC Davis Health to test a new antibody cocktail (REGN-COV2) as a prevention and treatment for COVID-19.

Albertson was awarded a grant to run the clinical trial at UC Davis Health. The grant comes from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The clinical trial is sponsored by Regeneron Pharmaceuticals. It is an adaptive phase I, II and III randomized, double-blinded, placebo-controlled study. It seeks to evaluate the efficacy and safety of REGN-COV2 (a combination of REGN10933+REGN10987 antibodies) in hospitalized adult patients with COVID-19. It builds on encouraging findings from a set of studies that showed the neutralizing impact of REGN10933 and REGN10987.

We are very excited to test this antibody combination as a possible treatment to COVID-19. We are all up and running on this clinical trial and will start patient recruitment soon."

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, UC Davis Health

At this time, there is no approved treatment that specifically targets SARS-CoV-2.

Disabling the SARS-CoV-2 spike protein

The spike proteins on the outer envelope of coronaviruses allow entry and bind to the host cells. They appear to be central to why SARS-CoV-2 is so infectious. Previous studies have found that the viral infectivity of coronaviruses such as SARS-CoV and MERS-CoV was reduced when neutralizing antibodies were used against spike protein, blocking the host cell entry.

Currently, there are multiple efforts to develop antibodies that target the spike protein. Regeneron is developing and testing fully human, neutralizing monoclonal antibodies (mAbs) directed against the spike protein of SARS-CoV-2 for the treatment and prevention of COVID-19.

Regeneron antibody cocktail as potential COVID-19 treatment

To this end, Regeneron developed the REGN-COV2 antibodies to bind to the SARS-CoV-2 spike protein and block its interaction with the host receptor, which is expected to neutralize the virus.

The clinical trial will test the safety, tolerability and efficacy of REGN-COV2 as a promising therapeutic strategy to reduce SARS-CoV-2 viral shedding and COVID-19 disease progression.

Information on the clinical study (# NCT04426695), titled Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19, can be found online. The clinical trial launched June 11.

Source:
Journal reference:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    The University of California, Davis. (2022, November 15). UC Davis Health tests new antibody combination as potential treatment for COVID-19. AZoLifeSciences. Retrieved on July 24, 2024 from https://www.azolifesciences.com/news/20200721/UC-Davis-Health-tests-new-antibody-combination-as-potential-treatment-for-COVID-19.aspx.

  • MLA

    The University of California, Davis. "UC Davis Health tests new antibody combination as potential treatment for COVID-19". AZoLifeSciences. 24 July 2024. <https://www.azolifesciences.com/news/20200721/UC-Davis-Health-tests-new-antibody-combination-as-potential-treatment-for-COVID-19.aspx>.

  • Chicago

    The University of California, Davis. "UC Davis Health tests new antibody combination as potential treatment for COVID-19". AZoLifeSciences. https://www.azolifesciences.com/news/20200721/UC-Davis-Health-tests-new-antibody-combination-as-potential-treatment-for-COVID-19.aspx. (accessed July 24, 2024).

  • Harvard

    The University of California, Davis. 2022. UC Davis Health tests new antibody combination as potential treatment for COVID-19. AZoLifeSciences, viewed 24 July 2024, https://www.azolifesciences.com/news/20200721/UC-Davis-Health-tests-new-antibody-combination-as-potential-treatment-for-COVID-19.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genome of the earliest common ancestor of all mammals identified